Loading
Cediranib is a tablet that blocks the blood-vessel growth signal VEGF. In alveolar soft part sarcoma, a rare very vascular sarcoma that ignores chemotherapy, a randomised trial showed it shrinks tumours and delays progression, although it was never licensed.
Cediranib (AZD2171) is AstraZeneca's oral inhibitor of VEGFR-1, -2 and -3. It was tested widely, including the ICON6 trial in relapsed ovarian cancer, but never gained approval; AstraZeneca withdrew its EU application (Zemfirza, relapsed ovarian cancer) on 19 September 2016 before a Commission decision. Its clearest activity is in alveolar soft part sarcoma: a National Cancer Institute phase 2 showed responses in a third of patients, and the randomised, placebo-controlled CASPS trial (Lancet Oncology, 2019) found a greater reduction in tumour size at 24 weeks and longer progression-free survival than placebo.
Cediranib remains an investigational drug available in some countries through trials or special access; other VEGFR inhibitors such as sunitinib, pazopanib and anlotinib, and checkpoint inhibitors such as atezolizumab, are used in practice. The alveolar soft part sarcoma page names it among the VEGFR-directed drugs that are active in the disease.
A potent inhibitor of all three VEGF receptors, with activity against PDGFR and KIT, that blocks tumour angiogenesis; alveolar soft part sarcoma is highly vascular and driven by the ASPSCR1-TFE3 fusion, which upregulates angiogenic genes. Connects to VEGF / VEGFR.
1.Cediranib slips into a pocket on VEGF / VEGFR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Cediranib" OR ABSTRACT:"Cediranib" OR TITLE:"AZD2171" OR ABSTRACT:"AZD2171" OR TITLE:"Recentin" OR ABSTRACT:"Recentin" OR TITLE:"Cediranib maleate" OR ABSTRACT:"Cediranib maleate" OR TITLE:"Zemfirza" OR ABSTRACT:"Zemfirza") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cediranib, not a curated reading list.
Shares Pazopanib and the tag subtype-drugs-wave.
Shares Small-molecule kinase inhibitors and the tag subtype-drugs-wave.
Shares AstraZeneca and the tag subtype-drugs-wave.
Shares Alveolar soft part sarcoma, Anlotinib, Small-molecule kinase inhibitors.
Shares Alveolar soft part sarcoma, Anlotinib, Small-molecule kinase inhibitors.
Shares Alveolar soft part sarcoma, Atezolizumab.